Cart
sales@molnova.com
Zolbetuximab
CAS No. 1496553-00-4
Zolbetuximab( —— )
Catalog No. M37695 CAS No. 1496553-00-4
Zolbetuximab(IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2.Zolbetuximab has potential antitumor activity, mediating killing of Claudin-18.2-positive cells through an immune effector mechanism.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 400 | Get Quote |
|
| 5MG | 620 | Get Quote |
|
| 10MG | 870 | Get Quote |
|
| 25MG | 1242 | Get Quote |
|
| 50MG | 1684 | Get Quote |
|
| 100MG | 2223 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameZolbetuximab
-
NoteResearch use only, not for human use.
-
Brief DescriptionZolbetuximab(IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2.Zolbetuximab has potential antitumor activity, mediating killing of Claudin-18.2-positive cells through an immune effector mechanism.
-
DescriptionZolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors.
-
In Vitro——
-
In VivoAnimal Model:mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model Dosage:200 μg alone or with 50 mg/kg Gemcitabine Administration:i.v.; i.p. (Gemcitabine)Result:Inhibited tumor growth in two models, and prevented lung metastasis formation.Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1496553-00-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kyuno D, et, al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers. 2022 Jan 2;10(1):1967080.?
molnova catalog
related products
-
UCL 2077
UCL 2077 is a subtype-selective blocker of the epilepsy-associated KCNQ channels and it also is a selective slow-afterhyperpolarization channel blocker.
-
Enterodiol
Enterodiol has antioxidant and immunomodulatory effects, it is able to pass the intestinal barrier and modulate cytokine production.
-
β-lonone
β-lonone is an end-ring analog of β-carotenoids which widely distributed in fruit and vegetableswith?anti-proliferative anti-metastatic.
